Denali Therapeutics Inc (DNLI) financials
Denali Therapeutics revenue and earnings by year
Denali Therapeutics's revenue was $331 million in the fiscal year to December 31, 2023, up 204.7% from the year before. Net income was -$145 million, -43.9% of revenue. Since the fiscal year to December 31, 2018, revenue has grown 20.7% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 6 fiscal years
| Fiscal year to | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|
| Revenue | 331 | 108 | 49 | 336 | 27 | 129 |
| Revenue growth | 204.7% | 122.9% | -85.5% | 1158.2% | -79.3% | — |
| Operating income | -197 | -341 | -296 | 63 | -213 | -46 |
| Operating margin | -59.5% | -314.2% | -607.8% | 18.7% | -799.1% | -35.9% |
| Net income | -145 | -326 | -291 | 71 | -198 | -36 |
| Net margin | -43.9% | -300.6% | -597.2% | 21.2% | -740.7% | -28.1% |
| Diluted EPS | -$1.06 | -$2.60 | -$2.39 | $0.63 | — | -$0.44 |
| Free cash flow | -371 | -263 | -220 | 413 | -169 | 47 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open DNLI in Markets.
See also: DNLI returns
No forecast, no recommendation. This page describes Denali Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.